Can quetiapine (Seroquel) cause premature ventricular or atrial contractions (extrasystoles), and how should they be managed?

Quetiapine and Extrasystoles

Quetiapine can cause premature ventricular contractions (PVCs) as a documented adverse effect, though the primary cardiac concern with this medication is QT prolongation rather than isolated ectopic beats.

Evidence for Quetiapine-Induced Extrasystoles

A case report directly demonstrates that quetiapine can induce frequent PVCs 1. In this case, a 17-year-old patient developed frequent monomorphic PVCs (0.6% burden initially, increasing to 7.1% with quetiapine readministration), which decreased to 1.1% after drug withdrawal. This establishes a clear temporal relationship between quetiapine exposure and PVC development.

Additionally, acute quetiapine overdose has been associated with ectopic atrial rhythms 2, suggesting the drug can trigger both atrial and ventricular ectopy under certain conditions.

Primary Cardiac Risk: QT Prolongation

The FDA label for quetiapine emphasizes QT prolongation as the main cardiac concern 3. While clinical trials showed no persistent QT increase, post-marketing surveillance revealed QT prolongation cases, particularly in:

• Overdose situations
• Patients with concomitant illness
• Those taking other QT-prolonging medications
• Patients with electrolyte imbalances

Recent large-scale data confirms this risk: over 13% of quetiapine users developed severe QT prolongation (QTc >500 ms or increase >60 ms), which was significantly associated with ventricular arrhythmias (OR 2.84) and sudden cardiac death (OR 2.29) 4.

Risk Stratification

High-risk patients requiring heightened monitoring include those with:

• Pre-existing cardiac arrhythmias (including bradycardia)
• Hypokalemia or hypomagnesemia
• Concomitant QT-prolonging medications
• Congenital long QT syndrome
• Cardiovascular disease, heart failure, or cardiac hypertrophy
• Advanced age
• Family history of QT prolongation

The 2014 European Heart Journal guideline classifies quetiapine among atypical antipsychotics with dose-dependent increased risk of sudden cardiac death 5.

Management Approach

For patients developing extrasystoles on quetiapine:

1. Obtain baseline and follow-up ECGs to assess:

   • QTc interval (not just rhythm abnormalities)
   • Frequency and morphology of ectopic beats
   • Presence of other conduction abnormalities

2. Check electrolytes immediately:

   • Potassium and magnesium levels
   • Correct any deficiencies before continuing therapy

3. Review medication list for other QT-prolonging agents (Class IA/III antiarrhythmics, other antipsychotics, certain antibiotics, methadone) 3

4. Risk-benefit assessment:

   • If PVCs are frequent (>1% burden) or symptomatic, consider dose reduction or discontinuation 1
   • If QTc exceeds 500 ms or increases >60 ms from baseline, strongly consider alternative therapy 4
   • Asymptomatic rare PVCs with normal QTc may be monitored without immediate discontinuation

5. Consider alternative antipsychotics if cardiac risk is unacceptable:

   • Aripiprazole and lurasidone have minimal QT prolongation risk 6
   • Avoid ziprasidone and iloperidone (highest QT risk)

Critical Pitfalls

• Do not rely on telemetry alone for QTc assessment; formal 12-lead ECGs provide more accurate measurements 7
• Do not assume quetiapine is "safe" at low doses; the risk is dose-dependent but present at therapeutic levels 5, 4
• Do not ignore isolated PVCs as benign; they may herald more serious arrhythmic potential, especially with concurrent QT prolongation 1
• Avoid combining quetiapine with other QT-prolonging drugs whenever possible 3

The evidence strongly supports that while extrasystoles can occur with quetiapine, the more pressing concern is QT prolongation and its associated risk of life-threatening ventricular arrhythmias and sudden death.